| Autor: |
Hinkson IV; Center for Biomedical Informatics and Information Technology, National Cancer InstituteRockville, MD, United States.; Science and Technology Policy Fellowship Program, American Association for the Advancement of ScienceWashington, DC, United States., Davidsen TM; Center for Biomedical Informatics and Information Technology, National Cancer InstituteRockville, MD, United States., Klemm JD; Center for Biomedical Informatics and Information Technology, National Cancer InstituteRockville, MD, United States., Kerlavage AR; Center for Biomedical Informatics and Information Technology, National Cancer InstituteRockville, MD, United States., Kibbe WA; Center for Biomedical Informatics and Information Technology, National Cancer InstituteRockville, MD, United States.; Department of Biostatistics and Bioinformatics, Duke University School of MedicineDurham, NC, United States., Chandramouliswaran I |
| Jazyk: |
angličtina |
| Zdroj: |
Frontiers in cell and developmental biology [Front Cell Dev Biol] 2017 Sep 21; Vol. 5, pp. 83. Date of Electronic Publication: 2017 Sep 21 (Print Publication: 2017). |
| DOI: |
10.3389/fcell.2017.00083 |
| Abstrakt: |
Advancements in next-generation sequencing and other -omics technologies are accelerating the detailed molecular characterization of individual patient tumors, and driving the evolution of precision medicine. Cancer is no longer considered a single disease, but rather, a diverse array of diseases wherein each patient has a unique collection of germline variants and somatic mutations. Molecular profiling of patient-derived samples has led to a data explosion that could help us understand the contributions of environment and germline to risk, therapeutic response, and outcome. To maximize the value of these data, an interdisciplinary approach is paramount. The National Cancer Institute (NCI) has initiated multiple projects to characterize tumor samples using multi-omic approaches. These projects harness the expertise of clinicians, biologists, computer scientists, and software engineers to investigate cancer biology and therapeutic response in multidisciplinary teams. Petabytes of cancer genomic, transcriptomic, epigenomic, proteomic, and imaging data have been generated by these projects. To address the data analysis challenges associated with these large datasets, the NCI has sponsored the development of the Genomic Data Commons (GDC) and three Cloud Resources. The GDC ensures data and metadata quality, ingests and harmonizes genomic data, and securely redistributes the data. During its pilot phase, the Cloud Resources tested multiple cloud-based approaches for enhancing data access, collaboration, computational scalability, resource democratization, and reproducibility. These NCI-led efforts are continuously being refined to better support open data practices and precision oncology, and to serve as building blocks of the NCI Cancer Research Data Commons. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
